| Schedule of Reconciled Consolidated Net Loss |
Segment revenue and significant segment expenses regularly reported to the CODM are included within the table below and are reconciled to condensed consolidated net loss: | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | Six months ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Revenue: | | | | | | | | | Product revenue, net | $ | 24,038 | | | $ | — | | | $ | 34,344 | | | $ | — | | | Collaboration and license revenue | 1,080 | | | 1,031 | | | 1,508 | | | 1,392 | | | Total revenue | 25,118 | | | 1,031 | | | 35,852 | | | 1,392 | | | Less: | | | | | | | | | Cost of product revenue | (154) | | | — | | | (354) | | | — | | | Research and development | | | | | | | | | Paltusotine | (13,702) | | | (14,478) | | | (25,571) | | | (31,729) | | | Atumelnant | (24,806) | | | (11,161) | | | (45,073) | | | (18,910) | | | Other research and development programs | (8,892) | | | (9,607) | | | (18,559) | | | (16,665) | | | Research and development personnel expenses | (29,330) | | | (25,138) | | | (59,979) | | | (50,765) | | | Research and development stock-based compensation | (14,004) | | | (13,099) | | | (33,332) | | | (24,918) | | | Other research and development (1) | (9,116) | | | (6,818) | | | (17,417) | | | (13,554) | | | Total research and development expenses | (99,850) | | | (80,301) | | | (199,931) | | | (156,541) | | | Selling, general and administrative | | | | | | | | | Other selling, general and administrative expenses (2) | (26,299) | | | (23,471) | | | (46,741) | | | (38,245) | | | Selling, general and administrative personnel expenses | (20,397) | | | (13,346) | | | (40,434) | | | (25,439) | | | Selling, general and administrative stock-based compensation | (10,877) | | | (13,025) | | | (21,229) | | | (21,684) | | | Total selling, general and administrative expenses | (57,573) | | | (49,842) | | | (108,404) | | | (85,368) | | | Total other income, net | 11,604 | | | 13,475 | | | 24,137 | | | 28,106 | | | Segment and consolidated net loss | $ | (120,855) | | | $ | (115,637) | | | $ | (248,700) | | | $ | (212,411) | |
(1)Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs, including depreciation, and other facility-based expenses, such as rent expense. (2)Other selling, general and administrative expenses is comprised of non-personnel related indirect costs incurred for the benefit of multiple administrative functions, including sales and marketing expenses, facility-related costs, legal and professional fees, insurance costs and costs to operate a public company.
|